|
1
|
Zitvogel L, Tesniere A and Kroemer G:
Cancer despite immunosurveillance: immunoselection and
immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang X, Ye D and Thorpe PE: Enhancing the
potency of a whole-cell breast cancer vaccine in mice with an
antibody-IL-2 immunocytokine that targets exposed
phosphatidylserine. Vaccine. 29:4785–4793. 2011. View Article : Google Scholar
|
|
3
|
Johnson S, Michalak M, Opas M and Eggleton
P: The ins and outs of calreticulin: from the ER lumen to the
extracellular space. Trends Cell Biol. 11:122–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Michalak M, Corbett EF, Mesaeli N, et al:
Calreticulin: one protein, one gene, many functions. Biochem J.
344:281–292. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trombetta ES and Parodi AJ: Quality
control and protein folding in the secretory pathway. Annu Rev Cell
Dev Biol. 19:649–676. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Trombetta ES: The contribution of
N-glycans and their processing in the endoplasmic reticulum
to glycoprotein biosynthesis. Glycobiology. 13:R77–R91. 2003.
|
|
7
|
Michalak M, Robert Parker JM and Opas M:
Ca2+ signaling and calcium binding chaperones of the
endoplasmic reticulum. Cell Calcium. 32:269–278. 2002.
|
|
8
|
Zhu Q, Zelinka P, White T and Tanzer ML:
Calreticulin-integrin bidirectional signaling complex. Biochem
Biophys Res Commun. 232:354–358. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwon MS, Park CS, Choi K, et al:
Calreticulin couples calcium release and calcium influx in
integrin-mediated calcium signaling. Mol Biol Cell. 11:1433–1443.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gray AJ, Park PW, Broekelmann TJ, et al:
The mitogenic effects of the B-chain of fibrinogen are mediated
through cell surface calreticulin. J Biol Chem. 270:26602–26606.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
White TK, Zhu Q and Tanzer ML: Cell
surface calreticulin is a putative mannoside lectin which triggers
mouse melanoma cell spreading. J Biol Chem. 270:15926–15929. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Obeid M, Tesniere A, Ghiringhelli F, et
al: Calreticulin exposure dictates the immunogenicity of cancer
cell death. Nat Med. 13:54–61. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Obeid M, Panaretakis T, Joza N, et al:
Calreticulin exposure is required for the immunogenicity of gamma
irradiation and UVC light-induced apoptosis. Cell Death Differ.
14:1848–1850. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spisek R and Dhodapkar MV: Towards a
better way to die with chemotherapy: role of heat shock protein
exposure on dying tumor cells. Cell Cycle. 6:1962–1965. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spisek R, Charalambous A, Mazumder A,
Vesole DH, Jagannath S and Dhodapkar MV: Bortezomib enhances
dendritic cell (DC)-mediated induction of immunity to human myeloma
via exposure of cell surface heat shock protein 90 on dying tumor
cells: therapeutic implications. Blood. 109:4839–4845. 2007.
View Article : Google Scholar
|
|
16
|
Tesniere A, Panaretakis T, Kepp O, et al:
Molecular characteristics of immunogenic cancer cell death. Cell
Death Differ. 15:3–12. 2008. View Article : Google Scholar
|
|
17
|
Panaretakis T, Joza N, Modjtahedi N, et
al: The co-translocation of ERp57 and calreticulin determines the
immunogenicity of cell death. Cell Death Differ. 15:1499–1509.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin Y, Han Y, Cao C, Ren Y, Li C and Wang
Y: Melanoma B16-F1 cells coated with fusion protein of mouse
calreticulin and virus G-protein coupled receptor induced the
antitumor immune response in Balb/C mice. Cancer Biol Ther.
11:574–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Copier J and Dalgleish A: Overview of
tumor cell-based vaccines. Int Rev Immunol. 25:297–319. 2006.
View Article : Google Scholar
|
|
20
|
de Gruijl TD, van den Eertwegh AJ, Pinedo
HM and Scheper RJ: Whole-cell cancer vaccination: from autologous
to allogeneic tumor- and dendritic cell-based vaccines. Cancer
Immunol Immunother. 57:1569–1577. 2008.PubMed/NCBI
|
|
21
|
Chiang CL, Benencia F and Coukos G: Whole
tumor antigen vaccines. Semin Immunol. 22:132–143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Copier J and Dalgleish A: Whole-cell
vaccines: a failure or a success waiting to happen? Curr Opin Mol
Ther. 12:14–20. 2010.PubMed/NCBI
|
|
23
|
Bodey B, Bodey B Jr, Siegel SE and Kaiser
HE: Failure of cancer vaccines: the significant limitations of this
approach to immunotherapy. Anticancer Res. 20:2665–2676.
2000.PubMed/NCBI
|
|
24
|
Cohen EP, Chopra A, O-Sullivan I and Kim
TS: Enhancing cellular cancer vaccines. Immunotherapy. 1:495–504.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fucikova J, Kralikova P, Fialova A, et al:
Human tumor cells killed by anthracyclines induce a tumor-specific
immune response. Cancer Res. 71:4821–4833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu C, Sandford G, Fei G and Nicholas J: G
protein selectivity determinant specified by a viral chemokine
receptor-conserved region in the C tail of the human herpes virus 8
G protein-coupled receptor. J Virol. 78:2460–2471. 2004. View Article : Google Scholar
|
|
27
|
Cao CY, Han Y, Ren YS and Wang YL:
Apoptotic B16-F1 cells coated with recombinant calreticulin
mediated anti-tumor immune response in mice. Chin J Cancer Res.
22:253–259. 2010. View Article : Google Scholar
|
